Want to see ENVB full AI Analyst Report?
ENVB Stock Chart & Stats
$1.29
-$0.01(-0.78%)
At close: 4:00 PM EDT
$1.29
-$0.01(-0.78%)
Day’s Range― - ―
52-Week Range$1.25 - $17.63
Previous CloseN/A
Volume62.46K
Average Volume (3M)781.31K
Market Cap
$4.90M
Enterprise Value-$1.98
Total Cash (Recent Filing)$4.91M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.34
Shares Outstanding3,681,884
10 Day Avg. Volume899,153
30 Day Avg. Volume781,309
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-315
Revenue Forecast (FY)$10.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving essentially zero debt reduces interest costs and lowers near-term solvency risk, preserving limited cash to fund R&D and trials. Over the next 2–6 months this structural absence of leverage improves financial flexibility and bargaining power with partners and lenders.
Improving Operating LossesA meaningful improvement in operating losses versus prior years signals better cost control and operational discipline. If sustained, this trend lengthens runway, reduces the cadence of external funding needs, and increases the chance to advance clinical milestones with lower incremental dilution.
Clinical-stage Neuroplastogenic PipelineA focused clinical-stage platform targeting mental-health disorders aligns with structural demand for novel therapies. The differentiated non-hallucinogenic neuroplastogenic approach can create durable scientific and partnership advantages if clinical data validate efficacy and safety.
Bears Say
No Revenue / Sustained LossesThe absence of product revenue and persistent large net losses mean the company cannot self-fund operations. Over multiple quarters this increases execution risk for clinical programs and extends dependence on external capital until commercialization or licensing occurs.
Persistent Negative Cash FlowSustained negative operating and free cash flow accelerates depletion of cash reserves and compresses runway. Without near-term revenue or material cost reduction, ongoing cash burn forces financing choices that can delay programs or dilute shareholders.
Reliance On Equity Raises (ATM) And Dilution RiskActive use of an at-the-market equity program and recent share sales indicate recurring capital dependence. Structurally, repeated equity issuance is dilutive and signals limited internal funding, constraining long-term shareholder value unless offset by revenue, partnerships, or major licensing deals.
Enveric Biosciences News
ENVB FAQ
What was Enveric Biosciences’s price range in the past 12 months?
Enveric Biosciences lowest stock price was $1.25 and its highest was $17.63 in the past 12 months.
What is Enveric Biosciences’s market cap?
Enveric Biosciences’s market cap is $4.90M.
When is Enveric Biosciences’s upcoming earnings report date?
Enveric Biosciences’s upcoming earnings report date is Aug 17, 2026 which is in 17 days.
How were Enveric Biosciences’s earnings last quarter?
Enveric Biosciences released its earnings results on May 15, 2026. The company reported -$1.082 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Enveric Biosciences overvalued?
According to Wall Street analysts Enveric Biosciences’s price is currently Overvalued.
Does Enveric Biosciences pay dividends?
Enveric Biosciences does not currently pay dividends.
What is Enveric Biosciences’s EPS estimate?
Enveric Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enveric Biosciences have?
Enveric Biosciences has 3,681,884 shares outstanding.
What happened to Enveric Biosciences’s price movement after its last earnings report?
Enveric Biosciences reported an EPS of -$1.082 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.747%.
Which hedge fund is a major shareholder of Enveric Biosciences?
Currently, no hedge funds are holding shares in ENVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enveric Biosciences
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
GT Biopharma
―
Artelo Biosciences
―
Ownership Overview
16.62% Insiders
0.22% Mutual Funds
0.46% Other Institutional Investors
81.22% Public Companies and
Individual Investors